Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: I. Effects on left ventricular performance and neurohormonal systems

Circulation

Volumn 96, Issue 7, 1997, Pages 2385-2396

  Spinale, Francis G ^a   De Gasparo, Marc ^b   Whitebread, Steve ^b   Hebbar, Latha ^a   Clair, Mark J ^a   Melton, D Mark ^a   Krombach, R Stephen ^a   Mukherjee, Rupak ^a   Iannini, Julie P ^a   O , Seung Jun ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Angiotensin cardiovascular disease; Heart failure; Myocardium

Indexed keywords

ANGIOTENSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; ENZYME INHIBITION; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART PACING; HEMODYNAMICS; HORMONAL REGULATION; HYPERTENSION; NONHUMAN; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SWINE; VASCULAR RESISTANCE;

EID: 0030846832     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.7.2385     Document Type: Article

References (69)

1. Lenfant C. Report of the task force on research in heart failure. Circulation. 1994;90:1118-1123.
2. Cohn JN, Francis GS. Cardiac failure: a revised paradigm. J Card Failure. 1995;1:261-266.
3. Cohn JN, Johnson GR, Shabetai R, Loeb H, Tristani F, Rector T, Smith R, Fletcher R, for the V-HeFT VA Cooperative Studies Group. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. Circulation. 1993; 87(suppl VI):VI-5-VI-16.
4. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435.
5. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
6. Pitt B. Use of converting enzyme inhibitors in patients with asymptomatic left ventricular dysfunction. J Am Coll Cardiol. 1993;22(4 suppl A):158A-161A.
7. Sabbah HN, Shimoyama H, Kono T, Gupta RC, Sharov VG, Scicli G, Levine TB, Goldstein S. Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction. Circulation. 1994;89:2852-2859.
8. 1-adrenoceptor blockade, converting enzyme inhibitor therapy, and angiotensin II subtype 1 receptor blockade on ventricular remodeling in the dog. Circulation. 1994;90:3034-3046.
9. Spinale FG, Holzgrefe HH, Mukherjee R, Hird RB, Walker JD, Arnim-Barker A, Powell JR, Koster WH. Angiotensin-converting enzyme inhibition and the progression of congestive cardiomyopathy: effects on left ventricular and myocyte structure and function. Circulation. 1995;92:562-568.
10. Cushman DW, Wang FL, Fung WC, Grover GJ, Harvey CM, Scales RJ, Mitch SL, DeForrest JM. Comparison in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of the angiotensin converting enzyme (ACE). Br J Clin Pharmacol. 1989; 28:115S-131S.
11. Jeanneret LJ. Modulation of proteolytic activity in tissues following chronic inhibition of angiotensin converting enzyme. Biochem Pharmacol. 1993;45:1447-1454.
12. Nolly H, Carbini LA, Scicli G, Carretero OA, Scicli G. A local kallikrein-kinin system is present in rat hearts. Hypertension. 1994; 23:919-923.
13. Ehring T, Baumgart D, Krajcar M, Mummelgen M, Kompa S, Heusch G. Attenuation of myocardial stunning by the ACE inhibitor ramiprilat through a signal cascade of bradykinin and prostaglandins but not nitric oxide. Circulation. 1994;90:1368-1385.
14. Gavras H. Angiotensin converting enzyme inhibition and the heart. Hypertension. 1994;23:813-818.
15. Gohlke P, Linz W, Scholkens BA, Kuwer I, Bartenbach S, Schnell A, Unger T. Angiotensin converting enzyme inhibition improves cardiac function: role of bradykinin. Hypertension. 1994;23:411-418.
16. Timmermans PBMW, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JAM, Smith RD. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 1993;45:205-251.
17. Crozier I, Ikram H, Awan N, Cleland J, Stephen N, Dickstein K, Frey M, Young J, Klinger G, Makris L, Rucinska E, for the Losartan Hemodynamic Study Group. Losartan in heart failure: hemodynamic effects and tolerability. Circulation. 1995;91:691-697.
18. 1 receptor subtype. Br J Pharmacol. 1993;110:761-771.
19. Meiracker AH, Admiraal PJJ, Janssen JA, Kroodsma JM, de Ronde WA, Boomsma F, Sissmann J, Blankestijn PJ, Mulder PG, Man In't Veld AJ. Hemodynamic and biochemical effects of the ATI receptor antagonist irbesartan in hypertension. Hypertension. 1995;25:22-29.
20. Azizi M, Chatellier G, Guyene TT, Murieta-Geoffroy D, Menard J. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium depleted normotensives. Circulation. 1995;92: 825-834.
21. Kanda T, Araki M, Nakano M, Imai S, Suzuki T, Murata K, Kobayashi I. Chronic effect of losartan in a murine model of dilated cardiomyopathy: comparison with captopril. J Pharmacol Exp Ther. 1995;273:955-958.
22. Urata H, Boehm KD, Philip A, Kinoshita A, Gabrovsek J, Bumpus FM, Husain A. Cellular localization and regional distribution of an angiotensin II forming chymase in the heart. J Clin Invest. 1993;91: 1269-1281.
23. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II forming pathways in normal and failing human hearts. Circ Res. 1990;66:883-890.
24. Spinale FG, Hendrick DA, Crawford FA, Smith AC, Hamada Y, Carabello BA. Chronic supraventricular tachycardia causes ventricular dysfunction and subendocardial injury in swine. Am J Physiol. 1990;259(Heart Circ Physiol 28):H218-H229.
25. Tomita M, Spinale FG, Crawford FA, Zile MR. Changes in left ventricular volume, mass, and function during development and regression of supraventricular tachycardia induced cardiomyopathy: disparity between recovery of systolic vs diastolic function. Circulation. 1991;83:635-644.
26. Travill CM, Williams TDM, Pate P, Song G, Chalmers J, Lightman SL, Sutton R, Noble MIM. Hemodynamic and neurohormonal response in heart failure produced by rapid ventricular pacing. Cardiovasc Res. 1992;26:783-790.
27. Spinale FG, Holzgrefe HH, Mukherjee R, Arthur SA, Child MJ, Powell JR, Koster WH. Left ventricular and myocyte structure and function with recovery from tachycardia induced cardiomyopathy. Am J Physiol. 1995;268:H836-H847.
28. Armstrong PW, Stopps TP, Ford SE, DeBold AJ. Rapid ventricular pacing in the dog: pathophysiologic studies of heart failure. Circulation. 1986;74:1075-1084.
29. Komamura K, Shannon RP, Ihara T, Shen YT, Mirsky I, Bishop SP, Vatner SF. Exhaustion of the Frank-Starling mechanism in conscious dogs with heart failure. Am J Physiol. 1993;265(4 pt 2): H1119-H1131.
30. Benedict CR, Weiner DH, Johnstone DE, Bourassa MG, Ghali JK, Nicklas J, Kirlin P, Greenberg B, Quinones MA, Yusuf S, for the SOLVD Investigators. Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: results of the Studies of Left Ventricular Dysfunction (SOLVD) registry. J Am Coll Cardiol. 1993;22:146A-153A.
31. Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, Zera P, Menlove R, Shah P, Jamieson S, Stinson EB. β1 and β2 adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective β1-receptor down regulation in heart failure. Circ Res. 1986;59:297-309.
32. Wei CM, Lerman A, Rodeheffer RJ, McGregor CGA, Brandt RR, Wright S, Heublein DM, Kao PC, Edwards WD, Burnett JC. Endothelin in human congestive heart failure. Circulation. 1994;89: 1580-1586.
33. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation. 1992;85: 504-509.
34. Baker KM, Booz GW, Dostal DE. Cardiac actions of angiotensin II: role of an intracardiac renin-angiotensin system. Annu Rev Physiol. 1992;54:227-241.
35. Hirsch AT, Talsness CE, Schunkert H, Paul M, Dzau VJ. Tissue specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res. 1991;69:475-482.
36. Macari D, Whitehread S, Cumin F, de Gasparo M, Levens N. Renal actions of the angiotensin AT2 receptor ligands CGP42112 and PD123319 after blockade of the renin-angiotensin system. Eur J Pharmacol. 1994;259:27-36.
37. Travill CM, Williams TDM, Pate P, Song G, Chalmers J, Lightman SL, Sutton R, Noble MIM. Haemodynamic and neurohumoral response in heart failure produced by rapid ventricular pacing. Cardiovasc Res. 1992;26:783-790.
38. Colan SD, Borrow KM, Neuman A. Left ventricular end-systolic wall stress-velocity of fiber shortening relation: a load-independent index of myocardial contractility. J Am Coll Cardiol. 1984;4:715-724.
39. Cushman D, Cheung H. Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung. Biochem Pharmacol. 1971;20:1637-1648.
40. de Gasparo M, Rogg H, Brink M, Wang L, Whitebread S, Bullock G, Erne P. Angiotensin II receptor subtypes and cardiac function. Eur Heart J. 1994;15(suppl D):98-103.
41. Rogg H, Schmid A, de Gasparo M. Identification and characterization of angiotensin II receptor subtypes in rabbit ventricular myocardium. Biochem Biophys Res Commun. 1990;173:416-422.
42. Rogg H, de Gasparo M, Graedel E, Stulz P, Burkart F, Eberhard M, Erne P. Angiotensin II receptor subtypes in human atria and evidence for alterations in patients with cardiac dysfunction. Eur Heart J. 1996;17:1112-1120.
43. Sakai S, Miyauchi T, Sakurai T, Kasuya Y, Ihara M, Yamaguchi I, Goto K, Sugishita Y. Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure. Circulation. 1996;93:1214-1222.
44. Moe GW, Angus C, Howard RJ, Parker TG, Armstrong PW. Evaluation of indices of left ventricular contractility and relaxation in evolving canine experimental heart failure. Cardiovasc Res. 1992; 26:362-366.
45. Spinale FG, Mukherjee R, Iannini JP, Whitebread S, Hebbar L, Clair MJ, Melton DM, Cox MH, Thomas PB, de Gasparo M. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing induced heart failure: effects on myocyte contractile processes. Circulation. 1997; 96:2397-2406.
46. Weber KT, Anversa P, Armstrong PW, Brilla CG, Burnett JC, Cruickshank JM, Devereux RB, Giles TD, Corsgaard N, Leier CV, Mendelsohn FAO, Motz WH, Mulvany MJ, Strauer BE. Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol. 1992;20:3-16.
47. Sadoshima J, Izumo S. Molecular characterization of angiotensin II induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts: critical role of AT1 receptor subtype. Circ Res. 1993;73: 413-423.
48. 2+ modulation. Circ Res. 1996;78:302-311.
49. Golfman LS, Hata T, Beamish RE, Dhalla NS. Role of endothelin in heart function in health and disease. Can J Cardiol. 1993;9: 635-653.
50. Tsutamoto T, Wada A, Maeda Y, Adachi T, Kinoshita M. Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. J Am Coll Cardiol. 1994;23:1427-1433.
51. Nootens M, Kaufmann I, Rector T, Toher C, Judd D, Francis GS, Rich S. Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. J Am Coll Cardiol. 1995;26: 1582-1585.
52. Kiowski W, Sutsch G, Hunziker P, Muller P, Kim J, Oechslin E, Schmitt R, Jones R, Bertel O. Evidence for endothelin-1 mediated vasoconstriction in severe chronic heart failure. Lancet. 1995;346: 732-736.
53. Sharpe DN, Coxon R. Hemodynamic effects of captopril in chronic heart failure: efficacy of low-dose treatment and comparison with prazosin. Am Heart J. 1982;104:1164-1171.
54. Fouad FM, Tarazi RC, Bravo EL, Hart NJ, Castle LW, Salcedo EE. Long-term control of congestive heart failure with captopril. Am J Cardiol. 1982;49:1489-1496.
55. Siurdsson A, Amtorp O, Gundersen T, Nilsson B, Remes J, Swedberg K, the Ramipril Trial Study Group. Neurohormonal activation in patients with mild or moderately severe congestive heart failure and effects of ramipril.. Br Heart J. 1994;72:422-427.
56. Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD. Effects of adding spironolactone to an ACE inhibitor in congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1995;76:1259-1265.
57. Pitt B. 'Escape' of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther. 1995;9:145-149.
58. Weber KT, Villarreal D. Aldosterone and anitaldosterone therapy in congestive heart failure. Am J Cardiol. 1993;71:3A-11A.
59. Weinberg EO, Schoen FJ, George D, Kagaya Y, Douglas PS, Litwin SE, Schunkert H, Benedict CR, Lorell BH. Angiotensin-converting enzyme inhibition prolongs survival and modifies the transition to heart failure in rats with pressure overload hypertrophy due to ascending aortic stenosis. Circulation. 1994;90: 1410-1422.
60. Chiba K, Moriyama S, Ishigai Y, Fukuzawa A, Irie K, Shibano T. Lack of correlation of hypotensive effects with prevention of cardiac hypertrophy by perindopril after ligation of rat coronary artery. Br J Pharmacol. 1994;112:837-842.
61. Ruzicka M, Skarda V, Leenen FHH. Effects of ACE inhibitors on circulating versus cardiac angiotensin II in volume overload-induced cardiac hypertrophy in rats. Circulation. 1995;92:3568-3573.
62. Kinoshita A, Urata H, Bumpus FM, Husain A. Measurement of angiotensin I converting enzyme inhibition in the heart. Circ Res. 1993;73:51-60.
63. Zisman LS, Abraham WT, Meixell GE, Vamvakias BN, Quaife RA, Lowes BD, Roden RL, Peacock SJ, Groves BM, Raynolds MV, Bristow MR, Perryman MB. Angiotensin II formation in the intact human heart. J Clin Invest. 1995;96:1490-1498.
64. Balcells E, Meng QC, Hageman GR, Palmer RW, Durand JN, Dell'Itallia LJ. Angiotensin II formation in dog heart is mediated by different pathways in-vivo and in-vitro. Am J Physiol. 1996;271: H417-H421.
65. 2 receptor subtypes in hypertrophied rat hearts. Am J Physiol. 1994;267:H844-H852.
66. Zagrosek-Regitz V, Friedel N, Heymann A, Bauer P, Neuß M, Rolfs A, Steffen C, Hildebrandt A, Hetzer R, Fleck E. Regulation, chamber localization and subtype distribution of angiotensin II receptors in human hearts. Circulation. 1995;91:1461-1471.
67. Berecek KH, Zhang L. Biochemistry and cell biology of angiotensin converting enzyme and converting enzyme inhibitors. In: Mukhopadhyay AK, Raizada MK, eds. Tissue Renin-Angiotensin Systems: Current Concepts of Local Regulators in Reproductive and Endocrine Organs. New York, NY: Plenum Press; 1995:141-168.
68. McDonald KM, Mock J, D'Aloia A, Parrish T, Hauer K, Francis G, Stillman A, Conn JN. Bradykinin antagonism inhibits the antigrowth effects of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. Circulation. 1995;91:2043-2048.
69. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L, for the CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation. 1990;82:1730-1736.